Insilico Medicine
End-to-end AI drug discovery from target to clinic.
💸 No earnings reported yet
What it is
A generative-AI biotech that took an idiopathic pulmonary fibrosis compound from target identification to Phase II in under 30 months, holding the sector's most credible end-to-end claim.
How AI plugs in
Generative deep-learning engines (PandaOmics for target discovery, Chemistry42 for molecule design) propose novel drug candidates end-to-end, taking programs from target to clinic without human-led screening.
Alternatives & related tools
Cradle
Generative AI protein engineering for the lab
Recursion Pharmaceuticals
AI-native biotech mapping biology at industrial scale.
Schrodinger
Physics-based computational platform for drug discovery.
Julius AI
AI data analyst for everyone
Chai Discovery
Frontier biomolecular structure-prediction models
EvolutionaryScale
ESM3 frontier protein language model
★ Reviews
No reviews yet — be the first.Your rating